• Optimization of animal models for Duchenne Muscular Dystrophy to test the efficacy/safety of a novel protein therapeutic.• Development of bioanalytical assays (ELISA, mass spectrometry) for quantitation of a novel protein drug in pharmacokinetic / pharmacodynamic studies.

• Optimization of animal models for Duchenne Muscular Dystrophy to test the efficacy/safety of a novel protein therapeutic.• Development of bioanalytical assays (ELISA, mass spectrometry) for quantitation of a novel protein drug in pharmacokinetic / pharmacodynamic studies.

• Developed an efficient peptidomics and glycoproteomics workflow for identification of novel plasma/platelet biomarkers of acute coronary syndrome. • Development of a microalgae-based air purifier. Microalgae extraction and analysis.

• Development of a microalgae-based air purifier and algae extraction technology for large-scale ambient air CO2 removal.• Raised pre-seed investment.• Acquired 7 Letters-of-intent from customers and partner companies for trial and purchase of our device.

• Personally developed (or advised on the development of) bioanalytical quantitation assays for peptides/proteins, small molecule drugs and their metabolites.

• Designed and performed preclinical in-vivo models (rats, mice, pigs) to study the efficacy and safety of novel anticoagulant peptides derived from snake venom and tick saliva. Data acquired was used for fundraising activities with venture capital firms and liaising with CROs for ADME-tox and Phase I studies.• Initiated fundraising activities with venture capital firms and liaised with CROs for ADME-tox and Phase I studies.• Developed bioanalytical assays (LC-SRM, enzyme-based) and performed in-vivo animal pharmacokinetic studies for the anticoagulant peptides in rats and pigs. • Engineered a Plexiglas perfusion chamber for the porcine ex-vivo stent thrombosis model, without prior knowledge of engineering/design technology (I had to self-learn everything!). This perfusion chamber is now being used for Phase 0 clinical studies of our anticoagulant peptide.• Wrote and amended IACUC protocols and liaised with the animal use committee to obtain protocol approvals. • Managed a team of 3 research assistants for animal surgery procedures.

Identification of ligands for the orphan nuclear receptor PPARy (a target for many Type II Diabetes drug) from transgenic zebrafish:- Development/optimization of a protein purification protocol of a tagged-PPARy receptor fusion protein transgenically expressed in zebrafish embryos.- Optimization of a mass spectrometry method for identification of the endogenous ligand.

Development of an antibody targeting the cadherin domain of the drosophila melanogaster Cad88c protein.- Molecular cloning of the sequence encoding for cad88c antigen region into an expression vector- Heterologous expression of the Cad88c antigenic domain in E. coli- Protein purification of the expressed Cad88c antigenic domain

Forward genetic screen to identify mutant Arabidopsis thaliana with resistance towards Pseudomonas syringae bacteria.

Liposome-based encapsulation of asiaticoside